Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

@article{Johnson1995Copolymer1R,
  title={Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis},
  author={K. P. Johnson and Benjamin Rix Brooks and J. A. Cohen and Corey C. Ford and Jonathan M. Goldstein and Robert P. Lisak and Lawrence W. Myers and Hillel S. Panitch and John W. Rose and R. Schiffer and Timothy L Vollmer and Leslie P. Weiner and Jerry S. Wolinsky},
  journal={Neurology},
  year={1995},
  volume={45},
  pages={1268 - 1276}
}
we studied copolymer 1 (Copaxone) in a multicenter (11-university) phase III trial of patients with relapsing-remitting multiple sclerosis (MS). Two hundred fifty-one patients were randomized to receive copolymer 1 (n = 125) or placebo (n = 126) at a dosage of 20 mg by daily subcutaneous injection for 2 years. The primary end point was a difference in the MS relapse rate. The final 2-year relapse rate was 1.19 ± 0.13 for patients receiving copolymer 1 and 1.68 ± 0.13 for those receiving placebo… Expand
Management of relapsing/remitting multiple sclerosis with copolymer I (Copaxone)
TLDR
Copolymer I (Copaxone) was evaluated in a multicenter, placebo-controlled, double-blind trial at 11 US universities and significantly, more patients were receiving copolymer 1 had improved during the study, while more patients on placebo showed neurological decline. Expand
Copolymer 1 (Glatiramer Acetate) in Relapsing Forms of Multiple Sclerosis: Open Multicenter Study of Alternate-Day Administration
TLDR
This preliminary open-label study suggests that alternate-day therapy has beneficial effects and is well tolerated, comparing favorably with the effects of daily injections of Copolymer 1 in patients with relapsing MS. Expand
Meta-Analysis of Clinical Trials with Copolymer 1 in Multiple Sclerosis
TLDR
Data suggest that glatiramer acetate represents an alternative to interferon treatment in relapsing-remitting multiple sclerosis, however, further evidence of efficacy is required to justify its use in clinical practice. Expand
Management of Relapsing-Remitting Multiple Sclerosis
SummarySubcutaneous (SC) interferon-β-1a (Rebif®1) is a disease-modifying therapy that demonstrates significant benefits on all outcome measures of clinical trials [relapse rate, relapse severity,Expand
INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A DOSE-FINDING TRIAL
TLDR
Although IV immunoglobulin (IVIG) treatment was well tolerated, this study did not substantiate a beneficial effect of IVIG in doses ranging from 0.2 to 0.4 g/kg, and seriously questions the utility of IVig for the treatment of relapsing-remitting multiple sclerosis. Expand
Benefits of glatiramer acetate on disability in relapsing–remitting multiple sclerosis An analysis by area under disability/time curves
TLDR
An analysis of data from a Phase III treatment trial illustrates the AUC summary measure technique and provides further evidence of the efficacy of glatiramer acetate in RRMS. Expand
Spotlight on Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis
TLDR
Subcutaneous glatiramer acetate 20 mg/day was significantly more effective than placebo for the primary outcome measure of each trial and reduces relapse rate and decreases MRI-assessed disease activity and burden. Expand
Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study
TLDR
It is concluded that GA is not beneficial for preventing attacks in most patients with NMOSD, particularly in aquaporin-4 antibody-positive cases. Expand
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
TLDR
This study demonstrates the sustained efficacy of glatiramer acetate in reducing the relapse rate and in slowing the accumulation of disability in patients with relapsing forms of multiple sclerosis. Expand
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
In a randomized, placebo-controlled, double-blind study, glatiramer acetate (Copaxone®) reduced the relapse rate and slowed accumulation of disability for patients with relapsing-remitting multipleExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis
TLDR
A significant difference at 24 months between placebo and Cop 1 at one but not the other center is found and two-year progression rates for two secondary end points, unconfirmed progression, and progression of 0.5 EDSS units, are significant. Expand
Effect of treatment with copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE)
TLDR
Treatment with Cop-1 or CTH inhibits clinical manifestations of acute EAE without suppressing inflammatory cell infiltrates or sensitization to MBP, and there was little effect on the pathologic index. Expand
Multiple sclerosis: Trial of a synthetic polypeptide
TLDR
A preliminary open trial examined the ability of COP I to alter the course of disease in 12 patients with chronic progressive and 4 with exacerbating‐remitting multiple sclerosis (MS), and no undersirable side reaction was noted in any patient. Expand
Failure of copolymer I to inhibit the human T‐cell response to myelin basic protein
TLDR
Tests on MBP-specific T-cell lines and clones from four subjects found no inhibition by Cop 1 of the human T- cell response to MBP. Expand
Rating neurologic impairment in multiple sclerosis
TLDR
A new Expanded Disability Status Scale (EDSS) is presented, with each of the former steps (1,2,3 … 9) now divided into two (1.0, 1.5, 2.0 … 9). Expand
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
TLDR
Today there is a need for more exact criteria than existed earlier in order to conduct therapeutic trials in multicenter programs, to compare epidemiological surveys, to evaluate new diagnostic procedures, and to estimate the activity of the disease process in MS. Expand
Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation
TLDR
It is demonstrated that Cop-1 inhibits the in vitro response of several antigen-specific murine T cell hybridomas restricted to I-A, and to a lesser extent, I-E. Expand
Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1.
TLDR
The results suggest that Cop 1 may be effective in suppression of experimental allergic encephalomyelitis, not only because of the selective stimulation of suppressor T cells, as it has been previously demonstrated, but also by specific inhibition of BP-specific effectors T cells. Expand
Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.
TLDR
The results suggest that Cop 1 can compete with BP for the binding to human major histocompatibility complex molecules and suggest a possible mechanism for the beneficial effect of Cop 1 in this disease. Expand
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide
TLDR
Three random basic copolymers of amino acids were tested for their effect on experimental allergic encephalomyelitis and one of them, denoted as Cop 1, showed a marked suppressive effect on the disease. Expand
...
1
2
3
...